Prasugrel
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Prasugrel |
| DrugBank ID | DB06209 |
| Brand Names (EU) | Efient |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.88% |
Approved Indication (EMA)
Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | pulmonary hypertension | 99.88% | DL |
| 2 | migraine disorder | 99.88% | DL |
| 3 | migraine with brainstem aura | 99.83% | DL |
| 4 | kyphoscoliotic heart disease | 99.81% | DL |
| 5 | rheumatoid arthritis | 99.74% | DL |
| 6 | homozygous familial hypercholesterolemia | 99.74% | DL |
| 7 | hypoalphalipoproteinemia | 99.72% | DL |
| 8 | migraine with or without aura, susceptibility to | 99.67% | DL |
| 9 | brachydactyly-syndactyly syndrome | 99.60% | DL |
| 10 | leprosy | 99.46% | DL |
| 11 | obsolete susceptibility to ischemic stroke | 99.46% | DL |
| 12 | atrophoderma vermiculata | 99.46% | DL |
| 13 | peripheral vascular disease | 99.43% | DL |
| 14 | hypertrichosis (disease) | 99.43% | DL |
| 15 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 99.42% | DL |
| 16 | pulmonary hypertension, primary, autosomal recessive | 99.38% | DL |
| 17 | Prinzmetal angina | 99.38% | DL |
| 18 | peripheral arterial disease | 99.38% | DL |
| 19 | obsolete familial combined hyperlipidemia | 99.32% | DL |
| 20 | ulerythema ophryogenesis | 99.31% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.